Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock

Abstract

The incidence of long-term skin scarring and orthopaedic sequelae was high (48% and 14%, respectively) in patients who survived MSS in childhood. The severity of these sequelae varied from mild to severe. Patients with scars or orthopaedic sequelae had significantly higher severity of illness scores.

The Orthopaedic Consequences of Childhood Meningococcal Septicaemia

“…Of those patients who survived the initial disease, 6.9% required an amputation at some level, concurring with 8% of survivors in Buysse et al [17]. Erickson and De Wals [19] noted that the most common amputation in their study (38.5% of patients) was of multiple toes, which was replicated by this study (55.6% of patients).…”

“…PICU an average of 2.4 years younger than those who do not, supporting previous studies [15][16][17]. This is likely to be a result of agedependent vulnerability of bone vasculature, as well as the stage of bone development and maturity [18].…”

“…Previous studies investigating the orthopaedic consequences of childhood meningococcal septicaemia have considered an unselected population [13][14][15][16][17][18][19][20][21][22][23]. As such, they are unable to give accurate demographic data.…”

Cost-effectiveness of vaccination against meningococcal B among Dutch infants

“…1 We assumed that 33% of survivors with scars, and all survivors with amputations, needed to be hospitalized again within a few weeks for treatment of scars or amputations. 40 Patients with cognitive difficulties, seizure disorders, visual disturbances, severe hearing loss and major clinical impairments might be eligible for special education or intensive institutional care. Approximately 3.6% of patients met these criteria, 2 of which 25% would require intensive institutional care and 50% special education.…”

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

“…[4][5][6][7][8][9][10][11] Over the last 15 years, conjugate vaccines have resulted in near elimination of endemic disease in countries with high coverage group C vaccine programs 12 and marked effect of group A vaccines in Africa. 13 In many countries, most disease is now caused by capsular group B N. meningitidis (MenB).…”